JP2022523047A5 - - Google Patents

Info

Publication number
JP2022523047A5
JP2022523047A5 JP2021543183A JP2021543183A JP2022523047A5 JP 2022523047 A5 JP2022523047 A5 JP 2022523047A5 JP 2021543183 A JP2021543183 A JP 2021543183A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2022523047 A5 JP2022523047 A5 JP 2022523047A5
Authority
JP
Japan
Prior art keywords
sequence number
human
antigen
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/051667 external-priority patent/WO2020152290A1/en
Publication of JP2022523047A publication Critical patent/JP2022523047A/ja
Publication of JP2022523047A5 publication Critical patent/JP2022523047A5/ja
Pending legal-status Critical Current

Links

JP2021543183A 2019-01-23 2020-01-23 Cd31競合剤およびその使用 Pending JP2022523047A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305086 2019-01-23
EP19305086.1 2019-01-23
PCT/EP2020/051667 WO2020152290A1 (en) 2019-01-23 2020-01-23 Cd31 competitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022523047A JP2022523047A (ja) 2022-04-21
JP2022523047A5 true JP2022523047A5 (cg-RX-API-DMAC7.html) 2023-02-01

Family

ID=65409014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543183A Pending JP2022523047A (ja) 2019-01-23 2020-01-23 Cd31競合剤およびその使用

Country Status (13)

Country Link
US (1) US20220089765A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914616A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523047A (cg-RX-API-DMAC7.html)
KR (1) KR20210119448A (cg-RX-API-DMAC7.html)
CN (1) CN113614107A (cg-RX-API-DMAC7.html)
AU (1) AU2020211728A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014574A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127520A1 (cg-RX-API-DMAC7.html)
IL (1) IL284962A (cg-RX-API-DMAC7.html)
MX (1) MX2021008672A (cg-RX-API-DMAC7.html)
SG (1) SG11202107941TA (cg-RX-API-DMAC7.html)
WO (1) WO2020152290A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
CN117567594B (zh) * 2023-11-30 2025-02-07 北京博奥森生物技术有限公司 一种模拟cd31线性分子抗原性的分支多肽制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN101287764B (zh) * 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
KR102770106B1 (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체

Similar Documents

Publication Publication Date Title
JP7027482B2 (ja) Gタンパク質共役受容体を標的化する抗体および使用の方法
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのc5抗体及び方法
JP7719897B2 (ja) Tslp関連疾患に対する治療薬の開発及び用途
JP2018138035A (ja) 静電的ステアリング(electrostatic steering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
CN111320693B (zh) 抗EphA4抗体
WO2019228405A1 (zh) 一种自免疫抑制剂及其应用
CN104203977A (zh) 结合肽聚糖识别蛋白1的抗体
RU2004121673A (ru) Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей
CN113906050B (zh) 抗EphA4抗体
JP2022542884A5 (cg-RX-API-DMAC7.html)
KR20120056800A (ko) 글루글루카곤 수용체에 대한 항체와 이의 사용
JP2025134864A5 (cg-RX-API-DMAC7.html)
WO2016119523A1 (zh) 全人源her2抗体的突变抗体及其编码基因和应用
US20240392001A1 (en) Lilrb2-specific monoclonal antibodies and methods of their use
JP7796049B2 (ja) 抗EphA4抗体
RU2021124077A (ru) Конкурент за связывание с антителом CD31 и его применение
JP7839108B2 (ja) 筋萎縮性側索硬化症の治療用医薬組成物
RU2816371C2 (ru) АНТИТЕЛО К EphA4
KR20100021657A (ko) 프로테아제 활성화된 수용체-1 (par1)의 길항제 항체
HK40105878A (en) Novel anti-masp-2 antibodies
JP2024541576A (ja) 新規特異的アンタゴニスト抗SIRPg抗体
HK40092741A (en) Anti-epha4 antibody
CN119585311A (zh) 结合大麻素受体cb1的抗体及其用途
CA3294208A1 (en) Anti-cd200r1 antibody and use thereof